Literature DB >> 30800721

Anti-MOG encephalitis mimicking small vessel CNS vasculitis.

Kristina Patterson1, Estibaliz Iglesias1, Maclean Nasrallah1, Verónica González-Álvarez1, Mariona Suñol1, Jordi Anton1, Albert Saiz1, Eric Lancaster1, Thaís Armangue1.   

Abstract

Objective: To report 2 patients with anti-myelin oligodendrocyte glycoprotein (MOG)-associated encephalitis who were initially misdiagnosed with small vessel primary CNS vasculitis.
Methods: Review of symptoms, MRI and neuropathologic features, and response to treatment. MOG antibodies were determined in serum and CSF using a cell-based assay.
Results: Symptoms included fever, headache, and progressive mental status changes and focal neurologic deficits. CSF studies revealed lymphocytic pleocytosis, and both patients had abnormal brain MRIs. Brain biopsy samples showed prominent lymphocytic infiltration of the wall of small vessels; these findings initially suggested small vessel CNS vasculitis, and both patients were treated accordingly. Although 1 patient had a relapsing-remitting course not responsive to cyclophosphamide, the other one (also treated with cyclophosphamide) did not relapse. Retrospective assessment of serum and CSF demonstrated MOG antibodies in both cases, and review of biopsy specimens showed absence of fibrinoid necrosis (a pathologic requirement for small vessel CNS vasculitis). Conclusions: Anti-MOG-associated encephalitis can be mistaken for small vessel CNS vasculitis. This is important because the diagnosis of anti-MOG-associated encephalitis does not require brain biopsy and can be established with a serologic test.

Entities:  

Year:  2019        PMID: 30800721      PMCID: PMC6384022          DOI: 10.1212/NXI.0000000000000538

Source DB:  PubMed          Journal:  Neurol Neuroimmunol Neuroinflamm        ISSN: 2332-7812


The diagnosis of small vessel primary CNS vasculitis is challenging because conventional and brain MRI angiography are negative, and brain biopsy remains as the only definite diagnostic test.[1] However, brain biopsy is invasive and may be uninformative because of sampling error. Here, we describe 2 patients with myelin oligodendrocyte glycoprotein (MOG) antibody–associated encephalitis[2] who were initially misdiagnosed with small vessel CNS vasculitis based on biopsy findings. Physicians should be aware of this potential misdiagnosis because it has important clinical implications.

Case 1

A 5-year-old boy presented with 2 weeks of frontal headache and fever. His physical examination showed decreased alertness and bilateral papilledema (table). Brain CT and MRI (figure 1A) were normal, and the CSF showed pleocytosis. Meningoencephalitis was suspected, and he was started on steroids and acyclovir. During the following days, he developed visual hallucinations. There was gradual clinical improvement until complete recovery, and the patient was discharged on steroid taper 1 month later. In the ensuing 4 months, he was readmitted 3 times for relapsing symptoms while weaning from steroids. Repeat brain MRI showed T2 abnormalities in the basal ganglia, cerebellar peduncles, and supratentorial white matter (figure 1B-D), and CSF pleocytosis was identified in all episodes (table). All relapses substantially improved after treatment with steroids. At the last relapse, a conventional brain angiography was inconclusive. Brain biopsy showed infiltrates of lymphocytes involving the wall of small vessels and perivascular areas accompanied by perivascular demyelination (figure 2A–D). The patient was diagnosed with primary CNS vasculitis, and he was started on monthly pulses of cyclophosphamide. After the 5th pulse, he developed acute right optic neuritis that was treated with steroids, resulting in little improvement. Extensive blood testing identified an elevation of lipoprotein A (also present in his asymptomatic father), and oral aspirin was added, together with mycophenolate mofetil (MMF) and prednisone. He remained clinically and radiologically stable (figure 1E), with a right eye visual deficit for 2 years; at this time, immunosuppression was weaned, and shortly after stopping the steroids (while on MMF and aspirin), he developed confusion and decreased level of consciousness. MRI showed extensive white matter abnormalities (figure 1F) and high serum titer of MOG antibodies (1:640). Retrospective assessment of stored serum and CSF obtained at onset of the disease were also positive for MOG antibodies (serum titer 1:20,480 and CSF 1:320, table). Review of the paraffin block containing the brain biopsy showed that the inflammatory infiltrates were not confined to the vessel wall and also involved the white and gray matter. With these findings, the patient was diagnosed with anti-MOG encephalitis, and treatment with rituximab, azathioprine, and low-dose prednisone was initiated. No more relapses were observed; at the last follow-up, 3 years later, he remained clinically and radiologically stable on azathioprine and low-dose prednisone (eventually discontinued), and the serum titer of MOG immunoglobulin G (IgG) antibodies had decreased (1:80) below the consensus limit of positivity (≥1:160).[2,3]
Table

Clinical and laboratory data of 2 patients with anti-MOG encephalitis initially misdiagnosed with small CNS vessel vasculitis

Figure 1

MRI of 2 patients with anti-MOG encephalitis initially misdiagnosed with small vessel CNS vasculitis

Patient 1: (A) Axial T2 MRI sequence showing no abnormalities at disease onset; (B) bilateral involvement of the basal ganglia 4 weeks after disease onset while steroids were being decreased; (C) left cerebral peduncle abnormality at 6-week follow-up; (D) asymmetric large hazy white matter and basal ganglia lesions at 4 months; (E) residual white matter lesions and enlargement of ventricles due to brain atrophy; and (F) new asymmetric large hazy white matter lesions 30 months after disease onset when steroids were discontinued. Patient 2: (G and H) Axial FLAIR sequences showing gyriform hyperintensities with edema similar to abnormalities previously reported in cases of anti–MOG-associated cortical encephalitis.[6]

Figure 2

Brain biopsy of 2 patients with anti-MOG encephalitis initially misdiagnosed with small vessel CNS vasculitis

In patient 1, biopsy of the right temporal lobe showed small vessel perivascular lymphocytic infiltration (A, hematoxylin-eosin staining; B, magnification of the vessel shown in panel A). Inflammatory infiltrates included T and B lymphocytes (not shown) in association with edema, perivascular demyelination, and reactive gliosis (C and D, luxol fast blue staining). In patient 2, biopsy of the left temporal lobe showed marked perivascular lymphocytic infiltrates involving the vessel wall (E, hematoxylin-eosin staining). The infiltrates were also composed of T lymphocytes (F, CD3 immunostaining), B lymphocytes (G, CD20 immunostaining), and macrophages (H, anti-CD68 immunostaining). Myelin staining did not show clear evidence of demyelination (not shown). No necrosis or fibrin deposition was identified (not shown). Scale bar 200 μm in A and C, 500 μm in E, and 100 μm in B, D, and F–H.

Clinical and laboratory data of 2 patients with anti-MOG encephalitis initially misdiagnosed with small CNS vessel vasculitis

MRI of 2 patients with anti-MOG encephalitis initially misdiagnosed with small vessel CNS vasculitis

Patient 1: (A) Axial T2 MRI sequence showing no abnormalities at disease onset; (B) bilateral involvement of the basal ganglia 4 weeks after disease onset while steroids were being decreased; (C) left cerebral peduncle abnormality at 6-week follow-up; (D) asymmetric large hazy white matter and basal ganglia lesions at 4 months; (E) residual white matter lesions and enlargement of ventricles due to brain atrophy; and (F) new asymmetric large hazy white matter lesions 30 months after disease onset when steroids were discontinued. Patient 2: (G and H) Axial FLAIR sequences showing gyriform hyperintensities with edema similar to abnormalities previously reported in cases of anti–MOG-associated cortical encephalitis.[6]

Brain biopsy of 2 patients with anti-MOG encephalitis initially misdiagnosed with small vessel CNS vasculitis

In patient 1, biopsy of the right temporal lobe showed small vessel perivascular lymphocytic infiltration (A, hematoxylin-eosin staining; B, magnification of the vessel shown in panel A). Inflammatory infiltrates included T and B lymphocytes (not shown) in association with edema, perivascular demyelination, and reactive gliosis (C and D, luxol fast blue staining). In patient 2, biopsy of the left temporal lobe showed marked perivascular lymphocytic infiltrates involving the vessel wall (E, hematoxylin-eosin staining). The infiltrates were also composed of T lymphocytes (F, CD3 immunostaining), B lymphocytes (G, CD20 immunostaining), and macrophages (H, anti-CD68 immunostaining). Myelin staining did not show clear evidence of demyelination (not shown). No necrosis or fibrin deposition was identified (not shown). Scale bar 200 μm in A and C, 500 μm in E, and 100 μm in B, D, and F–H.

Case 2

A 39-year-old woman with a history of ulcerative colitis treated with mesalamine and budesonide developed severe, progressive left temporo-parietal headache associated with nausea and photophobia. Shortly after neurologic symptom onset, she developed intermittent fever. Peripheral leukocytosis with neutrophilic predominance and elevated C-reactive protein were identified (table). Brain MRI showed hyperintense gyriform fluid-attenuated inversion recovery signal over the left temporal, parietal, and occipital lobes (figure 1G–H). CSF analysis showed pleocytosis and elevated protein concentration, and the patient was started on empiric antibiotics and acyclovir. Six days later, she developed expressive aphasia, confusion, and agitation, and bilateral VI cranial nerve palsies. Repeat brain MRI showed no changes, and CT angiography demonstrated no clear evidence of vasculitis. A biopsy of the left parietal lobe and dura showed interstitial and perivascular lymphocytic infiltrates with marked involvement of the vessel wall (figure 2E–H). There was no clear evidence of demyelination (data not shown). These findings led to suspect CNS vasculitis, and high-dose IV steroids and oral cyclophosphamide were started. Four months later, cyclophosphamide was discontinued because of elevated transaminases. The dose of prednisone was tapered over the course of 2 years. During the follow-up, the brain MRI normalized at 4 months and the neurologic examination at 9 months; her only complaints were mild aphasia when tired and chronic daily headache. Retrospective analysis of stored CSF obtained by the time of symptom onset showed MOG-IgG antibodies (1:8).

Discussion

We describe 2 patients initially diagnosed with small vessel CNS vasculitis but who in fact had anti–MOG-associated encephalitis. The first patient received standard treatment for CNS vasculitis, including cyclophosphamide and steroid-sparing drugs. Although this treatment led to initial stabilization of symptoms, the patient developed new relapses until he was transitioned to a B-cell depletion therapy with good clinical and serologic response. In the second patient, the finding of MOG antibodies did not change the treatment strategy because she was already clinically stable; however, an earlier detection of these antibodies could have prevented the brain biopsy. In retrospect, none of these patients fulfilled the criteria for small vessel CNS vasculitis. Although the presence of inflammatory cells in the vessel walls is sufficient to diagnose medium or large vessel vasculitis, signs of vessel damage such as fibrin deposition and/or necrosis (absent in our patients) must also be present to meet the criteria for small vessel vasculitis. Diapedesis of leukocytes takes place in small vessels, and the presence of inflammatory cells in the walls does not necessarily imply a pathologic process. Moreover, the pathology of CNS vasculitis is usually focal or segmental, and the brain biopsy specimen can be negative or not meet the full diagnostic criteria.[4] As our patients reveal, the presence of lymphoid cells in vessel walls must be interpreted with caution, particularly when the differential diagnosis includes encephalitis with lymphocytic infiltrates. In this context, the presence of lymphocytes in the brain parenchyma away from the vessel walls favors secondary involvement of the vessels rather than a primary vasculitic process. Whether other cases of anti-MOG encephalitis may have been misdiagnosed as CNS vasculitis is unknown. There are reports of patients diagnosed with CNS small vessel vasculitis by brain biopsy who later developed myelitis or optic neuritis[5] (symptoms suggestive of MOG encephalitis),[2,3] making us to postulate that this misdiagnosis may not be unusual.
  6 in total

Review 1.  Primary central nervous system vasculitis: pathology and mechanisms.

Authors:  Caterina Giannini; Carlo Salvarani; Gene Hunder; Robert D Brown
Journal:  Acta Neuropathol       Date:  2012-03-16       Impact factor: 17.088

Review 2.  Childhood central nervous system vasculitis.

Authors:  Susanne Benseler; Daniela Pohl
Journal:  Handb Clin Neurol       Date:  2013

3.  Angiography-negative primary central nervous system vasculitis in children: a newly recognized inflammatory central nervous system disease.

Authors:  Susanne M Benseler; Gabrielle deVeber; Cynthia Hawkins; Rayfel Schneider; Pascal N Tyrrell; Richard I Aviv; Derek Armstrong; Ronald M Laxer; Earl D Silverman
Journal:  Arthritis Rheum       Date:  2005-07

4.  Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease.

Authors:  Romana Höftberger; María Sepulveda; Thaís Armangue; Yolanda Blanco; Kevin Rostásy; Alvaro Cobo Calvo; Javier Olascoaga; Lluís Ramió-Torrentà; Markus Reindl; Julián Benito-León; Bonaventura Casanova; Georgina Arrambide; Lidia Sabater; Francesc Graus; Josep Dalmau; Albert Saiz
Journal:  Mult Scler       Date:  2014-10-24       Impact factor: 6.312

5.  MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy.

Authors:  Ryo Ogawa; Ichiro Nakashima; Toshiyuki Takahashi; Kimihiko Kaneko; Tetsuya Akaishi; Yoshiki Takai; Douglas Kazutoshi Sato; Shuhei Nishiyama; Tatsuro Misu; Hiroshi Kuroda; Masashi Aoki; Kazuo Fujihara
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-01-16

Review 6.  MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.

Authors:  S Jarius; F Paul; O Aktas; N Asgari; R C Dale; J de Seze; D Franciotta; K Fujihara; A Jacob; H J Kim; I Kleiter; T Kümpfel; M Levy; J Palace; K Ruprecht; A Saiz; C Trebst; B G Weinshenker; B Wildemann
Journal:  J Neuroinflammation       Date:  2018-05-03       Impact factor: 8.322

  6 in total
  10 in total

1.  Unilateral cortical FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis with Seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome.

Authors:  A Budhram; A Mirian; C Le; S M Hosseini-Moghaddam; M Sharma; M W Nicolle
Journal:  J Neurol       Date:  2019-06-26       Impact factor: 4.849

Review 2.  Using the World Apheresis Association Registry Helps to Improve the Treatment Quality of Therapeutic Apheresis.

Authors:  Bernd Stegmayr; Elizabeth Newman; Volker Witt; Kurt Derfler; Gerda Leitner; Sunny Eloot; Annemieke Dhondt; Dries Deeren; Jan Ptak; Milan Blaha; Mirka Lanska; Zdenka Gasova; Zdenka Bhuiyan-Ludvikova; Radomira Hrdlickova; Wolfgang Ramlow; Heinrich Prophet; Jan T Kielstein; Giancarlo Liumbruno; Elena Mori; Antanas Griskevicius; Judita Audzijoniene; Hans Vrielink; Eva Rombout-Sestrienkova; Astrid Aandahl; Aleksandar Sikole; Jorge Tomaz; Katarina Lalic; Ines Bojanic; Virginia Strineholm; Bo Brink; Gösta Berlin; Josefina Dykes; Thomas Nilsson; Torsten Eich; Henrik Hadimeri; Gunilla Welander; Sandra Ortega Sanchez; Osman Ilhan; Colwyn Poole
Journal:  Transfus Med Hemother       Date:  2021-01-05       Impact factor: 3.747

Review 3.  Risk Factors from Pregnancy to Adulthood in Multiple Sclerosis Outcome.

Authors:  Enrique González-Madrid; Ma Andreina Rangel-Ramírez; María José Mendoza-León; Oscar Álvarez-Mardones; Pablo A González; Alexis M Kalergis; Ma Cecilia Opazo; Claudia A Riedel
Journal:  Int J Mol Sci       Date:  2022-06-25       Impact factor: 6.208

4.  Brain Atrophy in Relapsing Optic Neuritis Is Associated With Crion Phenotype.

Authors:  Laura Navarro Cantó; Sara Carratalá Boscá; Carmen Alcalá Vicente; Sara Gil-Perontín; Francisco Pérez-Miralles; Jessica Castillo Villalba; Laura Cubas Nuñez; Bonaventura Casanova Estruch
Journal:  Front Neurol       Date:  2019-11-01       Impact factor: 4.003

5.  The difference of the retinal structural and microvascular characteristics in patients with MOGAD-ON and AQP4-ON.

Authors:  Yajun Yao; Xindi Li; Yun Xu; Xiaofang Liang; Liu Yang; Fu-Dong Shi; Xinghu Zhang; De-Cai Tian; Xuxiang Zhang
Journal:  BMC Neurol       Date:  2022-08-27       Impact factor: 2.903

6.  Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient.

Authors:  Tania Cellucci; Heather Van Mater; Francesc Graus; Eyal Muscal; William Gallentine; Marisa S Klein-Gitelman; Susanne M Benseler; Jennifer Frankovich; Mark P Gorman; Keith Van Haren; Josep Dalmau; Russell C Dale
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-01-17

7.  N2 year in review.

Authors:  Josep Dalmau; Marinos C Dalakas; Dennis L Kolson; Friedemann Paul; Scott S Zamvil
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-12-12

8.  Myelin Oligodendrocyte Glycoprotein Antibody Associated Cerebral Cortical Encephalitis: Case Reports and Review of Literature.

Authors:  Hang Shu; Manqiu Ding; Pei Shang; Jia Song; Yue Lang; Li Cui
Journal:  Front Hum Neurosci       Date:  2022-01-03       Impact factor: 3.169

9.  GRP78 Antibodies Are Associated With Blood-Brain Barrier Breakdown in Anti-Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorder.

Authors:  Fumitaka Shimizu; Ryo Ogawa; Yoichi Mizukami; Kenji Watanabe; Kanako Hara; Chihiro Kadono; Toshiyuki Takahashi; Tatsuro Misu; Yukio Takeshita; Yasuteru Sano; Miwako Fujisawa; Toshihiko Maeda; Ichiro Nakashima; Kazuo Fujihara; Takashi Kanda
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-11-01

Review 10.  Clinical and neuroimaging findings in MOGAD-MRI and OCT.

Authors:  Frederik Bartels; Angelo Lu; Frederike Cosima Oertel; Carsten Finke; Friedemann Paul; Claudia Chien
Journal:  Clin Exp Immunol       Date:  2021-07-18       Impact factor: 4.330

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.